Harnessing AI, Immunophenotyping, and Drug Sensitivity Testing for Individualized Canine Lymphoma Treatment

How can veterinary oncologists harness artificial intelligence alongside patient-specific diagnostics to improve treatment planning for canine lymphoma? This session will explore the real-world clinical utility of ImpriMed’s Personalized Prediction Profile (PPP), a precision medicine platform that integrates advanced lymphoma phenotyping (PARR, flow cytometry, MHC Class II expression), individual drug sensitivity testing from the patient’s own live cancer cells, and clinical data into machine-learning models.

Dr. Kevin Choy, a board-certified medical oncologist at BluePearl Pet Hospital (Kirkland, WA), will share his experience using ImpriMed in practice over the past five years. Through a series of clinical cases, he will demonstrate how PPP helps identify which anticancer drugs are most likely to be effective for each individual patient — whether newly diagnosed or relapsed — allowing for confident, informed chemotherapy selection decisions. This approach has helped streamline treatment planning, preserve client resources, and improve clinical outcomes. Attendees will gain a practical understanding of how AI can be combined with ex vivo testing and phenotyping to deliver truly personalized cancer care for canine lymphoma patients.